Home         Forums  

Go Back   Marrowforums > Bone Marrow Failure Diseases > PNH
Register FAQ Search Today's Posts Mark Forums Read

PNH Paroxysmal nocturnal hemoglobinuria

Reply
 
Thread Tools Search this Thread
  #1  
Old Sat Jul 7, 2018, 10:52 PM
Susan Susan is offline
Member
 
Join Date: Aug 2006
Location: Chicago, Il
Posts: 101
Two PNH Drug Trials Going Well:Update

Go to Apellis's Clinical Trials and see the two PNH trials status reports so far. One is PHAROAH, the other is PADDOCK.

http://www.apellis.com/clinical-trials.html

Here are the summaries:

APL-2 Monotherapy Holds Promise for Paroxymal Nocturnal Hemoglobinuria Patients
JULY 04, 2018
Krista Rossi
A new drug under development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, acquired, life-threatening blood disease, has been shown to be beneficial in participants enrolled 2 ongoing phase 1b trials—PHAROAH and PADDOCK.

The drug in question? Apellis Pharmaceuticals Inc.’s APL-2, a first-in-class treatment developed to target C3; in fact, it has the potential to significantly improve hemoglobin (Hb) levels in eculizumab-treated patients suffering from anemia, according to the pharmaceutical company.

Currently, the only approved drug for PNH therapy is eculizumab (Solaris). However, a recent study showed that 70% of patients treated with eculizumab were anemic and had hemoglobin levels below 12.0 g/dL.

The 2 proof-of-concept clinical trials are a part of the PNH program, which allows for participants with PNH to switch therapies, going from eculizumab to APL-2 monotherapy after 1 month of co-treatment. The overarching goal is to improve hematological parameters, particularly hemoglobin.

In the PHAROAH trial, which is assessing the ability of APL-2 to benefit PNH patients on treatment with eculizumab who are severely anemic and transfusion-dependent, participants are being treated with APL-2 in addition to eculizumab. After at least 1 year of co-treatment, several patients have been switched to APL-2 monotherapy.

The 32-week data from the trial released in December 2017 included 4 out of 6 patients who remained in the study as of week 32 and received co-treatment of eculizumab and APL-2 at 270 mg/day. Key findings included the observance of no needed transfusions, a successful reduction in dosing of eculizumab, and successful weaning from eculizumab.

“It was initially very encouraging to see the significant improvements in these significantly anemic patients when APL-2 was added to Soliri,” commented Anita Hill, lead consultant for the National PNH Service at the Leeds Teaching Hospitals, In the United Kingdom, in a recent statement. “To see APL-2 maintain the same hematological benefits when dosing with Soliris was reduced in all and weaned entirely in three of four patients is impressive.”

In the PADDOCK trial, APL-2 is being evaluated for safety and efficacy in PNH patients who have not been previously treated with eculizumab. According to the data collected in April 2018, 8 patients not previously treated with eculizumab after daily subcutaneous administration with 270 mg/day of APL-2 for at least 28 days reported that APL-2 increased Hb levels and reduced lactate dehydrogenase (LDH). Additional key findings included improved hemoglobin and other anemia markers.

“The data generated by APL-2 in treatment-naïve patients with PNH are impressive compared to our experience with Soliri,” added Peter Hillmen, MB ChB, PhD, professor of experimental hematology at the University of Leeds. “The early experience of APL-2 demonstrates that inhibiting C3 controls extravascular as well as intravascular hemolysis unlike inhibition of C5 where continued extravascular hemolysis is frequently problematic.”

To date, subcutaneous APL-2 has been found to be well tolerated with cumulative systemic exposure of over 12 patient years of treatment on APL-2, according to a recent news release. Furthermore, no significant infections or thromboembolic events have been noted.
“We are especially pleased to see APL-2 monotherapy helping a range of patients, including those who are severely anemic and continue to suffer while being treated with high doses of eculizumab,” emphasized Cedric Francois, MD, PhD, co-founder and CEO of Apellis. “We are encouraged by these data that support our belief that many rare and autoimmune conditions can be treated through C3 inhibition.”
__________________
AA/PNH Dx 1998, Warfarin, Soliris
Reply With Quote
Reply


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
ACH-4471 in trials for PNH treatment Marrowforums Clinical Trials 0 Thu Mar 29, 2018 01:23 PM
Learning About Clinical Trials and Finding Clinical Trials Marrowforums Clinical Trials 0 Wed Jun 3, 2015 05:10 PM
New PNH Drug Survey - Patient Preferences C3TRIS Drugs and Drug Treatments 4 Sat Mar 28, 2015 10:08 PM
AMY-101 for PNH Gains Orphan Drug Status Marrowforums PNH 0 Wed Nov 26, 2014 01:01 AM
PNH Webinar, September 2009 Marrowforums News and Events 0 Mon Sep 14, 2009 04:43 PM


All times are GMT -4. The time now is 11:34 PM.


Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2018, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright © 2006-2018 Marrowforums.org